Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Castle Biosciences ( (CSTL) ) just unveiled an update.
On May 5, 2025, Castle Biosciences reported a 21% increase in Q1 2025 revenue to $88 million compared to the same period in 2024, driven by a 33% rise in test reports for core products. The company raised its full-year revenue guidance to $287-297 million, reflecting strong growth and successful execution in its test portfolio. A significant milestone was achieved with over 200,000 orders for DecisionDx-Melanoma, which has been shown to improve patient survival rates. The company also announced the discontinuation of the IDgenetix test offering, effective May 2025, impacting its financials with a net loss of $25.8 million for the quarter.
Spark’s Take on CSTL Stock
According to Spark, TipRanks’ AI Analyst, CSTL is a Outperform.
Castle Biosciences is well-positioned financially with strong revenue growth and profitability improvements. However, technical analysis presents mixed signals, and the high P/E ratio suggests potential overvaluation. The potential Medicare coverage loss poses a risk, though the company shows resilience and growth potential. These factors collectively give the stock a moderate score.
To see Spark’s full report on CSTL stock, click here.
More about Castle Biosciences
Castle Biosciences is a company in the healthcare industry focused on improving health through innovative diagnostic tests that guide patient care. Their primary products include DecisionDx®-Melanoma, DecisionDx®-SCC, and TissueCypher®, with a market focus on dermatology and oncology.
YTD Price Performance: -30.99%
Average Trading Volume: 435,285
Technical Sentiment Signal: Buy
Current Market Cap: $558.1M
See more insights into CSTL stock on TipRanks’ Stock Analysis page.